New bone putty could improve spinal surgery outcomes
NCT ID NCT07044206
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two bone substitutes used during spinal fusion surgery for disc degeneration. One is a new material designed to help bones fuse more effectively. Researchers will track 100 adults for 12 months to see if the new substitute improves pain, disability, and fusion rates compared to the standard option.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MagnetOs bone substitute
- What this could lead to
- If successful, this could lead to better bone fusion after spinal surgery, reducing pain and the need for repeat operations.
- What could go wrong
- This is a small, early-stage study with only 100 participants. The new bone substitute may not work better than existing options, and surgery always carries risks like infection or nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged between 18 and 80 years inclusive * Oswestry Disability Index (ODI) \>25 * Chronic low back pain and/or radicular pain lasting for more than 6 months * Failure of medical and rehabilitative treatment * Patient presenting with one of the following: grade 1 degenerative spondylolisthesis without isthmic lysis, or disc degeneration, or mixed pathology (degeneration and lumbar stenosis) * Patient eligible for anterior approach spinal fusion surgery with interbody cage Exclusion Criteria: * History of spinal surgery at the lumbar level, excluding isolated discectomies for disc herniation * Confirmed osteoporosis * Surgical fusion at an adjacent level * Contraindication to Magnetos Putty or GlassBone Putty: 1. Use of medications interfering with calcium metabolism 2. Severe systemic or metabolic bone disorders affecting bone healing or lesions 3. Untreated acute or chronic infection requiring appropriate therapy 4. Patients with severe trauma and open external wounds near the defect site, at risk of infection 5. Known allergy to bioactive glass or its components (Ca2+, PO43-, Na+, and Si(OH)4), polyethylene glycol, and/or glycerol 6. Patients who have undergone or will undergo chemotherapy or radiotherapy at or near the implantation site 7. Severe renal or hepatic infections 8. Unrepaired dural tear in craniospinal surgery * Patients requiring placement of more than one implant * Subject unable to read and/or write fluent French, or illiterate * Subject already participating in another interventional clinical trial that could interfere with this study * Uncontrolled psychiatric illness * Lack of written informed consent after a reflection period * Individuals with a dependency or employment relationship with the sponsor or investigator * Subject enrolled in another study with an ongoing exclusion period (Article L1121-12) * Subject not affiliated with or not a beneficiary of the French social security system (L1121-8-1) * Protected populations under French Public Health Code: 1. Pregnant or breastfeeding women (L. 1121-5) 2. Individuals deprived of liberty (art. L. 1121-6) (by judicial, administrative decision or involuntary hospitalization) 3. Protected adults (under guardianship, curatorship, or legal protection) (L. 1121-8) * Women planning to become pregnant within the year
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Degenerative disc disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Montpellier
RECRUITINGMontpellier, France, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A conversation before spine surgery could change how patients recover
- Can a new bone graft match the gold standard for spinal fusion?
- Can a nanotube surface help spinal bones fuse faster?
- Can a growth factor from donor bone improve spinal fusion?
- 3D-Printed spinal cages could revolutionize back surgery
- Bone scan may help avoid unnecessary back surgery